2 papers
stat.AP2020
A Seamless Phase I/II Platform Design with a Time-To-Event Efficacy Endpoint for Potential COVID-19 Therapies
Thomas Jaki, Helen Barnett, Andrew Titman +1
In the search for effective treatments for COVID-19, initial emphasis has been on re-purposed treatments. To maximise the chances of finding successful treatments, novel treatments…
stat.ME2017
Subgroup analysis of treatment effects for misclassified biomarkers with time-to-event data
Fang Wan, Andrew C. Titman, Thomas F. Jaki
Analysing subgroups defined by biomarkers is of increasing importance in clinical research. In some situations the biomarker is subject to misclassification error, meaning the true…